⚠️ Research Use Only – Not for Human or Veterinary Use
The compounds discussed in this article are not approved for human or veterinary use. They have not been approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. All products referenced are sold strictly for laboratory and research use only. Nothing in this article constitutes medical advice.
BPC-157 Dosage: What the Preclinical Evidence Actually Shows
Understanding the right BPC-157 dosage is the difference between meaningful research outcomes and wasted resources. This guide synthesizes peer-reviewed animal model data, dosing frameworks referenced in compounding pharmacy settings, and researcher-reported protocols to provide evidence-grounded context. Whether you are evaluating subcutaneous injection doses, oral administration research, or peptide stacking strategies, every recommendation here traces back to published preclinical literature. No human clinical trials have validated these protocols.
What Is BPC-157 and Why Does Dosage Matter?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a larger protective protein (BPC) found naturally in human gastric juice. The peptide itself does not occur naturally; it is a laboratory-synthesized fragment of the parent protein. Since the early 1990s, BPC-157 has been studied extensively in animal models for its effects on tissue repair, angiogenesis (the formation of new blood vessels), and gastrointestinal cytoprotection (the shielding of stomach and intestinal lining from damage). A comprehensive 2010 review by Sikiric et al. documented BPC-157’s pharmacological activity across more than a dozen injury models, establishing it as one of the most broadly studied peptides in preclinical research.
The Pentadecapeptide Structure
BPC-157’s partial sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) gives it notable stability in acidic environments, a property that distinguishes it from most peptides, which degrade rapidly in gastric conditions. This stability is relevant to dosage research because it raises the possibility of oral bioavailability, a delivery route most peptides cannot support. Researchers investigating BPC-157 dosage must account for this structural characteristic when designing protocols.
From Lab to Clinical Interest
While BPC-157 remains a research compound without FDA approval for human therapeutic use, its consistent results across animal models have generated significant clinical interest. Compounding pharmacies have begun formulating BPC-157 under physician supervision, bringing questions about proper BPC-157 dosing from academic laboratories into clinical consultation rooms. It is important to note that compounding pharmacy formulations are prepared under state and federal regulatory oversight, while research-grade peptides are manufactured for laboratory use and are not held to the same pharmaceutical production standards. The gap between preclinical data and clinical application makes understanding dose-response relationships essential for any researcher evaluating this peptide.
BPC-157 Dose Protocols by Research Application
Research on BPC-157 dose protocols varies significantly by the target tissue and injury model under investigation. Animal studies have used doses ranging from 10 mcg/kg to 50 mcg/kg, administered intraperitoneally (injected into the abdominal cavity), subcutaneously (under the skin), intragastrically (delivered directly to the stomach), or topically. Translating these to human-equivalent doses requires careful allometric scaling (a mathematical method for adjusting doses between species based on body surface area), a process that introduces inherent uncertainty.
Musculoskeletal and Tendon Research
Tendon and ligament injury models represent one of the most extensively studied applications for BPC-157. A 2018 study by Seiwerth et al. demonstrated accelerated Achilles tendon healing in rats at doses of 10 mcg/kg administered intraperitoneally. The study observed increased collagen organization and improved biomechanical strength compared to controls.
The most frequently cited dose in tendon healing research, showing statistically significant improvements in collagen fiber alignment and tensile strength in rat Achilles tendon transection models. This is an animal dose; human-equivalent dosing has not been validated in clinical trials.
Seiwerth et al., 2018, Current Pharmaceutical DesignWhen scaled allometrically to a 75 kg human using FDA guidance on dose conversion, 10 mcg/kg in rats approximates 200 to 500 mcg per day in humans, the range most commonly referenced in compounding pharmacy protocols. Practitioners referencing BPC-157 injection dose protocols typically start at the lower end of this range and adjust based on clinical response and the specific condition being addressed. These are practitioner-reported approaches, not published clinical trial findings.
Gastrointestinal Cytoprotection
BPC-157’s derivation from a gastric protein makes gastrointestinal research a natural focus. Vukojevic et al. (2020) demonstrated dose-dependent gastroprotective effects in NSAID-induced gastric lesion models in animals, with both systemic injection and intragastric administration showing efficacy. Oral BPC-157 dosing in these studies used similar mcg/kg ranges as injectable protocols, suggesting the peptide retains biological activity through the GI tract in these models.
Key Dosing Observations in GI Research
Researchers noted that intragastric administration at 10 mcg/kg produced effects comparable to intraperitoneal injection at the same dose in animal models, an unusual finding for a peptide compound. This supports the hypothesis that BPC-157’s gastric acid stability translates to functional oral bioavailability in rodents, though human pharmacokinetic data confirming this remains absent from published literature.
| Research Application | Animal Dose (mcg/kg) | Route | Duration | Key Finding |
|---|---|---|---|---|
| Tendon healing | 10 | Intraperitoneal | 14 to 28 days | Accelerated collagen organization |
| Gastric ulcer | 10 | Intragastric / IP | 7 to 14 days | Dose-dependent cytoprotection |
| Muscle crush injury | 10 to 50 | IP / Local | 14 days | Improved muscle fiber repair |
| Nerve transection | 10 | IP | 21 to 28 days | Enhanced nerve regeneration markers |
| Inflammatory bowel | 10 | Intragastric | 14 days | Reduced inflammatory markers |
Neuroprotective Research
A smaller but growing body of research examines BPC-157 in traumatic brain injury and peripheral nerve damage models in animals. Studies consistently use the 10 mcg/kg dose that has become standard across BPC-157 research, with administration periods typically extending 21 to 28 days. Enhanced expression of growth factors including VEGF (vascular endothelial growth factor, a protein that stimulates blood vessel formation) and nerve growth factor has been observed in these models, suggesting dose-dependent neurotrophic activity in the tested species.
Research Protocol Insight
- Most published BPC-157 studies use daily single-dose administration rather than split dosing
- Local injection near the injury site has shown comparable or superior outcomes to systemic administration in some tendon models
- Duration of 14 to 28 days covers the majority of published protocols across all tissue types
BPC-157 Injection Dose vs. Oral Administration
Route of administration is one of the most consequential variables in any BPC-157 dose protocol. Unlike most peptide compounds, BPC-157’s demonstrated gastric stability opens the door to oral delivery in animal models, but the research picture is more nuanced than forum posts suggest.
Subcutaneous and Intramuscular Protocols
Subcutaneous injection remains the most common route in both animal research and compounding pharmacy protocols. The rationale is straightforward: injectable delivery bypasses gastrointestinal absorption variables, providing more predictable bioavailability. Compounding pharmacies formulating BPC-157 typically prepare lyophilized powder requiring reconstitution with bacteriostatic water.
Research protocols using subcutaneous administration generally inject within proximity of the target tissue, for example, near an injured tendon rather than a distant site. While head-to-head comparisons between local and systemic subcutaneous injection are limited, several studies note enhanced local effects when the injection site corresponds to the injury location.
Oral Bioavailability Considerations
BPC-157’s stability in gastric acid is well-documented in laboratory assays, and multiple animal studies demonstrate biological activity via intragastric administration. However, “activity” in an animal model does not equal confirmed oral bioavailability in the pharmacokinetic sense. No published study has measured serum peptide levels after oral BPC-157 administration in humans.
What the Animal Data Shows
In rat models of gastric ulcer and inflammatory bowel disease, oral (intragastric) BPC-157 at 10 mcg/kg produced statistically significant protection comparable to intraperitoneal injection. For researchers investigating BPC-157 in preclinical GI models, this suggests oral delivery is a viable research route, but extrapolation to human oral capsule formulations remains speculative without pharmacokinetic confirmation.
Reconstitution and Dosing Accuracy
For researchers using injectable BPC-157, accurate reconstitution is critical to achieving the intended BPC-157 mcg per day. A standard 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. Drawing 0.1 mL (10 units on an insulin syringe) delivers 250 mcg, the lower end of the common estimated dosing range.
Reconstitution Reference
- 5 mg vial + 2 mL BAC water = 2,500 mcg/mL (250 mcg per 0.1 mL)
- 5 mg vial + 1 mL BAC water = 5,000 mcg/mL (500 mcg per 0.1 mL)
- Always direct the stream against the vial wall; never inject directly onto the lyophilized pellet
Read related research on peptide reconstitution best practices →
BPC-157 Cycle Length and Dosing Schedules
Determining the optimal BPC-157 cycle length requires balancing research objectives against the available evidence on duration-dependent effects. Most published animal studies administer BPC-157 daily for 14 to 28 days, with some extending to 6 weeks for chronic injury models.
Standard Research Cycle Frameworks
The most common BPC-157 dosing schedule in published literature follows a simple daily protocol: one injection per day at a fixed mcg/kg dose for a defined period. No published study has demonstrated superiority of twice-daily over once-daily dosing at equivalent total daily doses, though split-dosing protocols appear in practitioner discussions.
Compounding pharmacy protocols referenced in clinical settings typically prescribe 4 to 6 week cycles, with some practitioners recommending an off-period of 2 to 4 weeks between cycles. The rationale for cycling, preventing receptor desensitization or tachyphylaxis (a diminishing response after repeated doses), is borrowed from pharmacological principles applied to other peptide therapies, not from BPC-157-specific data.
Cycling vs. Continuous Administration
No published study has directly compared cycled versus continuous BPC-157 administration for any outcome measure. The absence of this data is itself an important research limitation. Animal studies showing no apparent toxicity at standard doses across 4 to 6 week periods provide some safety context, but long-term continuous use data remains unavailable.
Stacking BPC-157: Research-Based Combination Protocols
Peptide stacking, administering two or more peptides concurrently, has gained significant attention in research and clinical settings. BPC-157 is most frequently stacked with TB-500 (Thymosin Beta-4), a peptide studied for its role in cell migration, anti-inflammatory signaling, and wound healing.
BPC-157 and TB-500 Stacking
The theoretical basis for combining BPC-157 with TB-500 rests on complementary mechanisms: BPC-157 promotes angiogenesis and collagen organization while TB-500 facilitates cell migration and reduces inflammation. No published study has tested this specific combination in a controlled animal model. Each peptide’s individual mechanism data provides the rationale used by researchers designing combination protocols, but mechanistic plausibility is not the same as empirical validation.
Compounding pharmacy stacking protocols typically maintain each peptide at its standard individual dose, for example, BPC-157 at 250 to 500 mcg/day alongside TB-500 at 2 to 5 mg administered 2 to 3 times weekly. These are practitioner-reported frameworks, not published research protocols.
Other Peptide Combinations Under Study
Additional stacking combinations appearing in clinical discussion include BPC-157 with GHK-Cu (a copper peptide studied for its wound healing and collagen synthesis effects) and BPC-157 with KPV (an anti-inflammatory tripeptide). In each case, the scientific rationale rests on non-overlapping mechanisms rather than published combination data. Researchers designing stacking protocols should note this distinction: mechanistic plausibility does not substitute for empirical combination testing.
⚠️ 5 Important Research Considerations for BPC-157 Dosage
Understanding these factors is essential for interpreting BPC-157 dosage research accurately and designing valid research protocols.
- No human clinical trials published: Despite 30+ years of research, virtually all BPC-157 dose-response data comes from animal models. Human pharmacokinetics (how the body absorbs, distributes, and eliminates the compound), bioavailability curves, and dose-toxicity profiles have not been established in peer-reviewed literature.
- Allometric dose scaling introduces uncertainty: Converting rat intraperitoneal doses (10 mcg/kg) to human subcutaneous doses involves multiple assumptions about metabolic rate, absorption, and body surface area. The commonly cited 200 to 500 mcg/day human range is an estimate, not a validated dose.
- FDA regulatory status: BPC-157 is not approved by the FDA for any human therapeutic use. The FDA’s compounding framework under Section 503B governs how outsourcing facilities may prepare certain compounds. The FDA has raised concerns about peptide compounding, and BPC-157’s specific regulatory status has been subject to increasing scrutiny.
- Source variability affects outcomes: Peptide purity, synthesis quality, and lyophilization process directly impact the active compound per milligram. Unverified sources may deliver doses significantly different from labeled content.
- Long-term safety data is absent: No study has evaluated BPC-157 administration beyond approximately 8 weeks in any model. Protocols exceeding this duration operate without published safety precedent.
Consequence Framework
Issue: Using unverified peptide sources. Research Impact: Actual delivered dose may deviate substantially from labeled potency, invalidating dose-response conclusions.
Issue: Applying rat doses directly to humans without allometric scaling. Research Impact: Potential for sub-therapeutic or supra-therapeutic dosing with unpredictable outcomes.
Dose extrapolation across species remains one of the most challenging aspects of translational peptide research. Without human pharmacokinetic data, all BPC-157 dosing frameworks carry inherent uncertainty. Principle adapted from FDA Guidance for Industry: Estimating Maximum Safe Starting Doses in Initial Clinical Trials
Sourcing research-grade peptides with verified purity documentation reduces source-related variables significantly. View Phoenix Peptide Labs quality standards →
✅ What the Research Shows About BPC-157 Dosage
Decades of preclinical investigation have established several consistent findings about BPC-157 dosing in animal models. A 2018 review by Sikiric et al. on BPC-157 and the nitric oxide system provides mechanistic context for many of these observations. All findings below are from preclinical (animal) studies unless otherwise noted.
Researchers who apply these principles, using verified-potency peptides at evidence-based dose ranges with proper reconstitution technique, are better positioned to generate reproducible and reliable experimental outcomes.
How to Source High-Quality BPC-157 for Your Research
The quality of BPC-157 you source directly determines whether your dosage protocol produces valid, reproducible data. Every variable discussed in this guide, from mcg per day calculations to cycle length planning, depends on the peptide in the vial being exactly what the label claims.
Purity and Potency Verification
High-performance liquid chromatography (HPLC) testing remains the gold standard for peptide purity verification. Research-grade BPC-157 should test at ≥98% purity with documented HPLC chromatograms available per batch. Mass spectrometry (MS) confirmation of molecular weight adds a second layer of identity verification, confirming the peptide sequence matches BPC-157’s known 1419.53 Da molecular weight.
Without these verifications, a researcher has no way to confirm that a “250 mcg dose” actually delivers 250 mcg of active BPC-157, and the dosing data becomes functionally meaningless. Source purity is consistently identified as a primary confounding variable in peptide research reproducibility failures.
Certificate of Analysis Standards
A legitimate Certificate of Analysis (COA) should include: HPLC purity percentage, mass spectrometry confirmation, amino acid analysis, endotoxin testing results, and sterility testing data (for injectable formulations). Each COA should be batch-specific; a generic COA without a lot number provides no meaningful quality assurance.
Researchers should request COAs directly from the supplier and verify that testing was performed by an independent, accredited laboratory rather than in-house only. This level of documentation is standard practice for compounded pharmaceutical products and should be expected for research-grade peptides.
Lyophilization and Formulation Quality
Proper lyophilization (freeze-drying) preserves peptide stability during storage and shipping. A well-lyophilized BPC-157 pellet appears as a uniform white or off-white cake that reconstitutes quickly and completely in bacteriostatic water. Collapsed, discolored, or crystalline pellets may indicate degradation during processing, which directly affects the active dose delivered.
Ready to source research-grade BPC-157? Shop Phoenix Peptide Labs’ verified peptide catalog →
Storage and Handling Protocol
Unreconstituted (lyophilized) BPC-157 should be stored at -20°C for long-term stability or 2 to 8°C (refrigerated) for short-term storage up to several weeks. Once reconstituted with bacteriostatic water, the solution should be refrigerated at 2 to 8°C and used within 28 days. Avoid repeated freeze-thaw cycles, which accelerate peptide degradation and reduce effective dosing accuracy.
Compounded vs. Research-Grade vs. Unverified Sources
Compounding pharmacies operating under state and federal oversight produce BPC-157 formulations with verified potency, sterility testing, and regulatory documentation trails. Research-grade peptides, such as those sold by Phoenix Peptide Labs, provide HPLC-verified purity and batch-specific COAs for laboratory use but are not manufactured under pharmaceutical compounding standards. Unverified sources, including overseas suppliers selling direct-to-consumer, frequently lack independent testing, batch traceability, and sterility assurance. For researchers establishing BPC-157 dosage protocols, the sourcing decision is foundational: your dose accuracy is only as good as your source quality.
Phoenix Peptide Labs Quality Assurance
- HPLC Verified: Every batch tested for ≥98% purity with documented chromatograms
- Certificate of Analysis: Batch-specific COAs with independent lab verification
- Sterility Tested: Injectable formulations tested for endotoxins and microbial contamination
- Research Grade: Lyophilized under controlled conditions for maximum stability and reconstitution accuracy
BPC-157 Dosage Comparison: Routes, Ranges & Research Models
This comparison consolidates BPC-157 dosing data across administration routes, dose ranges, and research applications studied in published animal model literature. It is designed as a reference tool for researchers designing protocols, not as human dosing guidance.
← Scroll to view all columns →| Variable | Subcutaneous / IP Injection | Intragastric (Oral) | Local / Topical | Intramuscular |
|---|---|---|---|---|
| Studied Dose Range | 10 to 50 mcg/kg/day | 10 mcg/kg/day | Application-dependent | 10 mcg/kg/day |
| Bioavailability | High (bypasses GI) | Variable (acid-stable) | Local tissue concentration | High (systemic) |
| Primary Research Use | Tendon, muscle, nerve | GI cytoprotection, IBD | Wound healing, burns | Muscle injury |
| Protocol Duration | 14 to 42 days | 7 to 28 days | 7 to 21 days | 14 to 28 days |
| Human-Equivalent Estimate | 200 to 500 mcg/day (unvalidated) | 200 to 500 mcg/day (unvalidated) | Cream/gel formulation | 200 to 500 mcg/day (unvalidated) |
| Purity Requirement | ≥98% HPLC | ≥98% HPLC | ≥95% HPLC | ≥98% HPLC |
| Human Clinical Data | None published | None published | None published | None published |
Data compiled from multiple PubMed-indexed studies (2010 to 2023). All doses refer to animal model research. Human-equivalent estimates use FDA allometric scaling guidance and are not validated clinical doses.
Who Uses BPC-157 Dosage Protocols in Research?
BPC-157 dosage research attracts a diverse range of investigators, each bringing distinct requirements for protocol design, purity verification, and sourcing standards.
The Prescribing Clinician
A physician evaluating compounded BPC-157 for patients with musculoskeletal or GI conditions under existing compounding frameworks. They need precise dosing references grounded in published research, verified potency documentation, and clear regulatory context to inform clinical decisions.
Have questions about your research needs? Contact our team →
The Independent Researcher Prioritizing Purity
A lab scientist or independent researcher running tissue healing or neuroprotection experiments who has experienced inconsistent results from unverified peptide sources. They need guaranteed potency per vial to generate reproducible dose-response data.
The Research Team Scaling an Experiment
A multi-site research team transitioning from pilot studies to larger-protocol experiments. They need consistent batch-to-batch potency, volume pricing transparency, and a supplier with documentation standards that satisfy institutional review requirements.
Frequently Asked Questions
The most commonly cited research dose is 10 mcg/kg/day in animal models. When scaled allometrically to human-equivalent estimates, this approximates 200 to 500 mcg per day, though this conversion carries inherent uncertainty because no human pharmacokinetic study has validated it.
Compounding pharmacy protocols referenced in clinical settings typically start at 250 mcg per day for subcutaneous injection, with some practitioners prescribing up to 500 mcg daily based on the condition being addressed and patient response.
For sourcing questions or documentation requests, contact our team.
Published animal studies typically administer BPC-157 daily for 14 to 28 days. Compounding pharmacy protocols often extend to 4 to 6 week cycles with a 2 to 4 week off-period between cycles, though this cycling structure is practitioner-derived rather than validated in published research.
The absence of long-term safety data beyond approximately 8 weeks means protocols exceeding that duration lack published precedent for safety evaluation.
For sourcing questions or technical specifications, contact Phoenix Peptide Labs directly.
Animal research demonstrates biological activity via both injectable and oral (intragastric) routes. BPC-157’s unusual gastric acid stability supports oral delivery in preclinical models, particularly for GI-targeted research applications.
However, no published human pharmacokinetic study has confirmed oral bioavailability. Injectable (subcutaneous) delivery remains the preferred route in compounding pharmacy protocols because it provides more predictable absorption and dosing accuracy.
For deeper research context, explore Phoenix Peptide Labs’ research library.
These represent two common dose levels within the estimated human-equivalent range derived from animal research. The 250 mcg dose corresponds to the lower end of allometric scaling from 10 mcg/kg rat studies, while 500 mcg falls at the higher end.
No published dose-comparison study in humans has determined whether 500 mcg produces superior outcomes to 250 mcg. Practitioner reports suggest starting at 250 mcg and adjusting based on response, but this approach is clinical convention rather than evidence-validated protocol. The research has not established whether BPC-157’s dose-response relationship is linear at human-equivalent doses.
Need technical specifications? Contact Phoenix Peptide Labs directly.
Need technical specifications or purity documentation? Contact Phoenix Peptide Labs directly →
No. BPC-157 is not FDA-approved for any human therapeutic indication. It is classified as a research compound. The FDA has addressed peptide compounding under its Section 503B framework, and BPC-157’s regulatory status has been subject to increasing scrutiny, including its consideration for the “Difficult to Compound” category.
All BPC-157 products are sold for laboratory and research use only. No registered clinical trials on ClinicalTrials.gov have published completed Phase II or Phase III human efficacy data for BPC-157 as of March 2026.
For regulatory updates and research context, explore our research resource hub.
Reconstitute by slowly injecting bacteriostatic water along the inner wall of the vial; never inject directly onto the lyophilized pellet. For a 5 mg vial, adding 2 mL of BAC water creates a 2,500 mcg/mL solution; adding 1 mL creates 5,000 mcg/mL.
Gently swirl (do not shake) until the pellet fully dissolves, producing a clear, colorless solution. Turbidity or particulate matter after reconstitution may indicate degradation. Use an insulin syringe calibrated in units for precise volume measurement: 10 units (0.1 mL) from a 2,500 mcg/mL solution delivers exactly 250 mcg.
For sourcing questions about our reconstitution-ready formulations, contact our team.
BPC-157 is frequently combined with TB-500 in research and clinical protocols based on complementary mechanisms of action. No published controlled study has tested this specific combination, but each peptide’s individual data provides mechanistic rationale for concurrent use.
Typical stacking protocols maintain standard individual doses: BPC-157 at 250 to 500 mcg daily alongside TB-500 at 2 to 5 mg administered 2 to 3 times weekly. These are practitioner-reported frameworks. Researchers should note that peptide-peptide interactions remain unstudied for most combinations, including BPC-157 and TB-500.
Browse our verified catalog for research-grade peptides at Phoenix Peptide Labs.
⚗️ Research Use Disclaimer
All content on this page is intended for informational and research purposes only. The compounds discussed are not approved by the FDA for human or veterinary therapeutic use and are not intended to diagnose, treat, cure, or prevent any disease. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a licensed medical professional before making any health-related decisions. Phoenix Peptide Labs products are sold strictly for laboratory and research use only.